Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies.

Slides:

Advertisements

Similar presentations

New Perspectives in Cancer Therapy Óren Smaletz Programa de Oncologia Hospital Israelita Albert Einstein.

Advertisements

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.

Samsung Genome Institute Samsung Medical Center

THE GENETIC BASIS OF CANCER

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Mouse Double Minute 2 (MDM2)

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis

سرطان الثدي Breast Cancer

Figure 1 Cellular processes involved in cancer development

Connecting COX-2 and Wnt in cancer

Underlying Mechanisms for Distant Metastasis - Molecular Biology

Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Figure 4 Possible combination therapies CDK4/6 inhibitors

Cell Communication.

Figure 1 A schematic representation of the HER2 signalling pathway

Selective estrogen receptor modulation

Volume 29, Issue 3, Pages (March 2016)

Apoptosis-targeted therapies for cancer

Cetuximab treatment increases IFNγ receptor 1 expression.

Volume 20, Issue 1, Pages 3-5 (July 2011)

A. glioblastoma with high (+++) KIT protein expression.

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

Schematic diagram of the proposed model depicting the functional relationship between EGFR and FASN in TKI resistance within EGFR mutant NSCLC cells Schematic.

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

NOTCH and PI3K-AKT Pathways Intertwined

Activated membrane signaling promotes survival in response to radiation. Activated membrane signaling promotes survival in response to radiation. Radiation.

Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR

Nat. Rev. Clin. Oncol. doi: /nrclinonc

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

Apoptosis-targeted therapies for cancer

Leto et al., Supplementary Figure S3

Apoptosis Cell Volume 108, Issue 2, Pages (January 2002)

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

The role of SRC-C3G-RAP1 signaling in transformation induced by CRKL

Expression of Signaling Mediators Downstream of EGF-Receptor Predict Sensitivity to Small Molecule Inhibitors Directed Against the EGF-Receptor Pathway

ADCC by T lymphocytes after transfection.

Comparison of ADCC by CD16V-transduced T lymphocytes and autologous NK cell. Comparison of ADCC by CD16V-transduced T lymphocytes and autologous NK cell.

Volume 1, Issue 3, Pages (April 2002)

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Friends with Benefits: Microenvironmental NRG1β and HGF Mediate HER2-Targeted Resistance in L-HER2+ and HER2E Breast Cancer Sarah B. Crist, Cyrus M.

Notch signaling from tumor cells: A new mechanism of angiogenesis

EGFR and cetuximab sensitivity of SCCUAT

MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification.

Simplified BRAF signaling network.

Potential model of HMQ1611 inhibiting breast cancer cell proliferation

Changes in signal transduction pathway induced by gefitinib.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Tivantinib does not inhibit MET function.

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

TYK2 signaling in T-ALL. TYK2 signaling in T-ALL. TYK2 activates STAT1 through phosphorylation downstream of the IL-10 receptor. Once phosphorylated, STAT.

The critical roles of miR-23a and miR-27a in colorectal cancer progression. miR-23a primarily increases cell motility through downregulation of its target.

EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. EGCG affects growth factor receptor signaling in H2111, H358, and H460.

Targeting the CBP–p300 synthetic lethal axis.

Establishment of HeLa/rtTAA/TRE-N1-IC cell line.

Successful targeting of ErbB2 receptors—is PTEN the key?

Connections between insulin/insulin-like growth factor 1 signaling and metabolic pathways in tumor cells. Connections between insulin/insulin-like growth.

HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition.

Regulation of signaling by wild-type and oncogenic Ras.

FGF19 amplification in liver cancer cell lines is associated with response to NVP-BGJ398. FGF19 amplification in liver cancer cell lines is associated.

Genomic and proteomic profiling of ovarian cancer cell lines.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

ENTPD5 expression correlates with EGFR and activated AKT levels in human NSCLC. A, percentages of PTEN-low lung adenocarcinoma cases with at least one.

Presentation transcript:

Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. A, MET gene amplification results in overexpression of the receptor and HER3 transphosphorylation in NSCLC cells in which EGFR is inhibited by specific TKIs. B, chromosome 7 duplication results in increased copy number of both HGF and MET and, thus, in increased MET-dependent signal transduction. This results in resistance to trastuzumab in breast cancer cells. C, upon EGFR inhibition, a substantial increase in MET expression is responsible for sustained prosurvival AKT signaling, leading to resistance to EGFR TKIs in glioblastoma. D, MET gene amplification, causing receptor overexpression and activation of downstream pathways, induces resistance to cetuximab and panitumumab in colorectal cancer. Simona Corso, and Silvia Giordano Cancer Discovery 2013;3:978-992 ©2013 by American Association for Cancer Research